Neurogene (NGNE) Price & Analysis

Compare

579 Followers

NGNE Stock Chart & Stats

$20.99

-$0.86(-3.93%)

At close: Jan 08 4:00 PM EST

$20.99

-$0.86(-3.93%)

Day’s Range― - ―

52-Week Range$6.88 - $37.27

Previous CloseN/A

Volume20.02K

Average Volume (3M)225.72K

Market Cap

$453.85M

Enterprise Value$51.22M

Total Cash (Recent Filing)$265.41M

Total Debt (Recent Filing)$10.21M

Price to Earnings (P/E)―

Beta2.81

Next Earnings

Mar 23, 2026

EPS Estimate

-1.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.99

Shares Outstanding14,271,916

10 Day Avg. Volume272,921

30 Day Avg. Volume225,725

Financial Highlights & Ratios

PEG Ratio-0.10

Price to Book (P/B)1.29

Price to Sales (P/S)434.14

P/FCF Ratio-5.62

Enterprise Value/Market Cap0.11

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-3.34

Enterprise Value/Ebitda-0.61

Forecast

1Y Price Target

$58.00

Price Target Upside176.32% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyNGN-401 is delivering deep, multi-domain, durable gains with zero regression, with patients exceeding pivotal responder bar.

Financial StabilityNeurogene has a cash runway sufficient to fund operations into the first quarter of 2028, providing financial stability.

Regulatory AdvancementsNGN-401 was selected by the FDA for its START Pilot Program and has received multiple designations including RMAT, ODD, Fast Track, and RPDD.

Bears Say

Investor SkepticismMisplaced commentary—not real investor skepticism—seems to be widening the valuation disconnect.

Regulatory ConcernsWe are not confident positive data at the six-month interim will be sufficient to support BLA submission and/or approval.

Valuation DisconnectDespite generating the most differentiated Rett dataset disclosed to date, NGNE has only gotten cheaper—despite zero investor pushback on the data itself.

Neurogene News

Neurogene reports Q3 EPS (99c) vs. ($1.19) last year

Cash, cash equivalents and short-term investments as of September 30, 2025 were $265.4 million. We expect cash, cash...

8d ago

NGNE

Neurogene price target raised to $70 from $65 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Neurogene (NGNE) to $70 from $65 and keeps a Buy...

8d ago

NGNE

Neurogene reports interim data in Pediatric Cohort from NGN-401 trial

Neurogene (NGNE) “announced positive, updated interim clinical data in the pediatric cohort (ages 4-10 cohort) from its ongoing...

9d ago

NGNE

Neurogene doses first patient in NGN-401 clinical trial

Neurogene (NGNE) announced that the first participant was dosed in the Embolden registrational clinical trial of NGN-401, a...

15d ago

NGNE

Neurogene price target raised to $65 from $45 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Neurogene (NGNE) to $65 from $45 and keeps a Buy...

21d ago

NGNE

Neurogene Inc. Reports Q3 2025 Financial Results

Neurogene Inc. ( ($NGNE) ) has released its Q3 earnings. Here is a breakdown of the information Neurogene...

3d ago

NGNE

Neurogene’s NGN-401: Strong Clinical Results and Market Misalignment Justify Buy Rating

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Neurogene today and set a price target of...

4d ago

NGNE

Promising Outlook for Neurogene’s NGN-401 in Rett Syndrome Treatment: Analyst Recommends ‘Buy’

William Blair analyst Sami Corwin has reiterated their bullish stance on NGNE stock, giving a Buy rating yesterday....

4d ago

NGNE

Positive Developments and Financial Stability Underpin Buy Rating for Neurogene’s ‘401 Program

TD Cowen analyst Ritu Baral has maintained their bullish stance on NGNE stock, giving a Buy rating on...

4d ago

NGNE

Neurogene Reports Positive Interim Results for Rett Syndrome Gene Therapy

Neurogene ( ($NGNE) ) just unveiled an announcement. Neurogene Inc. reported positive interim data from its NGN-401 Phase...

7d ago

NGNE

Neurogene’s NGN-401: Advancements and Growth Potential Drive Buy Rating and Raised Price Target

Neurogene, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from H.C....

8d ago

NGNE

Neurogene’s NGN-401: Promising Phase I/II Results and Strategic Advancements Justify Buy Rating

William Blair analyst Sami Corwin has maintained their bullish stance on NGNE stock, giving a Buy rating on...

8d ago

NGNE

Neurogene Announces Positive Interim Data for NGN-401

An announcement from Neurogene ( ($NGNE) ) is now available. On November 12, 2025, Neurogene Inc. announced positive...

9d ago

NGNE

Optimistic Buy Rating for Neurogene: Advancements in NGN-401 Therapy and Strategic Developments

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Neurogene. The associated price target remains...

14d ago

NGNE

NGNE FAQ

What was Neurogene’s price range in the past 12 months?

Neurogene lowest stock price was $6.88 and its highest was $37.27 in the past 12 months.

What is Neurogene’s market cap?

Neurogene’s market cap is $453.85M.

When is Neurogene’s upcoming earnings report date?

Neurogene’s upcoming earnings report date is Mar 23, 2026 which is in 122 days.

How were Neurogene’s earnings last quarter?

Neurogene released its earnings results on Nov 13, 2025. The company reported -$0.99 earnings per share for the quarter, beating the consensus estimate of -$1.249 by $0.259.

Is Neurogene overvalued?

According to Wall Street analysts Neurogene’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Neurogene pay dividends?

Neurogene does not currently pay dividends.

What is Neurogene’s EPS estimate?

Neurogene’s EPS estimate is -1.18.

How many shares outstanding does Neurogene have?

Neurogene has 14,271,916 shares outstanding.

What happened to Neurogene’s price movement after its last earnings report?

Neurogene reported an EPS of -$0.99 in its last earnings report, beating expectations of -$1.249. Following the earnings report the stock price went down -14.043%.

Which hedge fund is a major shareholder of Neurogene?

Currently, no hedge funds are holding shares in NGNE

Neurogene Stock Smart Score

Neutral

Fundamentals

Return on Equity

-42.25%

Trailing 12-Months

Asset Growth

65.34%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neurogene

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Neurogene (NGNE) Earnings & Revenues

Historic Earnings Reports

NGNE Stock 12 Month Forecast

Average Price Target

$58.00

▲(176.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","71":"$71","23.75":"$23.8","39.5":"$39.5","55.25":"$55.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$58.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$46.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,23.75,39.5,55.25,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.26,37.00923076923077,39.75846153846154,42.50769230769231,45.25692307692307,48.00615384615385,50.755384615384614,53.504615384615384,56.253846153846155,59.003076923076925,61.752307692307696,64.50153846153846,67.25076923076924,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.26,36.08615384615384,37.91230769230769,39.738461538461536,41.56461538461538,43.39076923076923,45.216923076923074,47.043076923076924,48.86923076923077,50.69538461538461,52.52153846153846,54.347692307692306,56.173846153846156,{"y":58,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.26,35.16307692307692,36.066153846153846,36.96923076923077,37.87230769230769,38.77538461538462,39.678461538461534,40.58153846153846,41.48461538461538,42.387692307692305,43.29076923076923,44.19384615384615,45.096923076923076,{"y":46,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.78,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.64,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >